Myeloma Minute: Treatments for Relapsed Patients
|
| INNOVATION | Latest Research
Considerations for Relapsed Myeloma Should Match Patient, Disease, and TherapyThe increasing number of myeloma treatment choices available to patients and clinicians today can make selecting the best approach at relapsed disease a challenge. In this article, IMF Chief Medical Officer Dr. Joseph Mikhael says the simplest way to approach treatment selection is to consider the 3 major classes of drugs available for these patients: proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies.
|
|
|
| EDUCATION | Teleconference
Myeloma Updates 2018: Best of ASCO/EHA/IMWGSave the Date: On Thursday, August, 2, 2018, at 4 p.m. PST / 7 p.m. EST, Dr. Brian G.M. Durie will explain what’s new and exciting from these recent major medical meetings:
|
|
|
| INSPIRATION | 5K Run/Walk
|
| INNOVATION | Research Grants
|
Sixth Annual Miracles for Myeloma 5K Race/Walk |
Calling All Researchers: Submit Your Grant Applications! |
|
The Sixth Annual Miracles for Myeloma 5K Race/Walk takes place on Saturday, September 22, 2018, beginning at 9:30 a.m. EST on a USATF-certified course in Oak Ridge Park, New Jersey. Check-in is from 8:00 to 9:15 a.m. that day, and registration ends on September 18 at midnight. Donations can be made until December, whether or not you are able to participate. Last year’s Miracles for Myeloma raised nearly $80,000 for myeloma research, funding a Senior Brian D. Novis Research Grant. Once again, we encourage you to help raise myeloma awareness and funds as we work toward a cure. |
The Brian D. Novis Research Grants honor the IMF’s founder Brian Novis, who succumbed to multiple myeloma in July of 1992. The grants are awarded to researchers working in the field of multiple myeloma and related disorders, including smoldering multiple myeloma (SMM), monoclonal gammopathy of undetermined significance (MGUS), and immunoglobulin-derived amyloidosis. The 2019 grants will support senior research projects with $80,000 each and junior research projects with $50,000 each. The deadline for submitting applications is Wednesday, August 1, 2018. |
|
|
|
|
| EDUCATION | Participate
10 Reasons to Attend an IMF Educational Outreach EventAt the IMF, our goal is to help others better understand multiple myeloma. That’s why we host educational outreach events. The IMF’s Patient & Family Seminars (P&FSs) and Regional Community Workshops (RCWs) provide patients, families, and caregivers with the most up-to-date myeloma information. We hope that once you attend a P&FS or RCW, you leave with a healthy dose of positivity and a greater sense of community. If you have yet to take part in one of these events, we encourage you to read this list of the 10 Reasons to Attend an IMF Educational Outreach Event.
|
|
|
| ACTION | Legislation
Firefighter Cancer Registry Act Signed into LawPresident Trump signed H.R. 931, the Firefighter Cancer Registry Act of 2017 into law on July 9, 2018. This new law will help researchers better understand cancer in firefighters. It creates a voluntary national registry to collect information about cancer incidence in firefighters. Firefighters put their lives on the line by charging into burning buildings and rescuing people from dangerous situations. Sadly, the elements firefighters are exposed to while performing their heroic work may cause cancers like multiple myeloma. The International Myeloma Foundation’s Senior Director of Public Policy and Advocacy, Robin Levy, said, “The IMF is optimistic the Firefighter Cancer Registry Act will provide our research community with the additional tools they need to better understand the increased cancer instances in firefighters. We thank Representatives Collins and Pascrell for their leadership on this important piece of legislation, and we believe this bill has potential to provide us with new knowledge that will help us keep firefighters safe on the job.” H.R. 931 was introduced by Rep. Collins (R-NY) and Rep. Bill Pascrell (D-NJ). The House previously passed H.R 931 on September 12, 2017. However, the bill was amended in the Senate and was readdressed by the House on June 22. View the full bill below.
|
|
|
| #ASKDRDURIE | Dr. Durie's Weekly Web Video Series
|
|
CLINICAL TRIALS |
EVENTS |
|
New isatuximab Clinical Trial: the IMROZ Study New isatuximab Clinical Trial: the IKEMA Study New ixazomib Clinical Trials: Learn How to Participate Join the conversation about myeloma on the Smart Patients Message Board |
July 21, 2018 August 1, 2018 August 24-25, 2018 September 22, 2018 September 22, 2018 September 22, 2018 |
Amgen, Celgene Corporation, Genentech, Janssen Oncology, and Takeda Oncology
and individuals like you who supported the IMF this year